Literature DB >> 22695914

Localized all-cell knock-out (LACKO) strategy is needed for studying adult stage diseases.

Xiaolan Du1, Ying Zhu, Fengtao Luo, Lin Chen.   

Abstract

Knock-out (KO) mouse models have been increasingly used to dissect the roles of genes in development, diseases, and injuries. The conventional KO approach allows study of the role of the targeted genes in all cells, but it sometimes results in embryonic lethality. Using the classical conditional KO approach, reseachers can avoid embryonic lethality, but they cannot modulate genes in a temporally controllable way. The inducible KO technique, which has been used to study the role of a gene in life processes at the adult stage, avoids the potential interfering role of changed structures and functions of the tissues/organs resulting from the early KO of the gene in the non-inducible conditional knock-out approach. However, it is difficult to develop clinically applicable therapies for some diseases or injuries based on the results obtained from inducible KO studies since the total summed role of the genes of interest in those diseases or injuries cannot be determined and, therefore, the potential therapeutic effects of the applied modulators of the activity of the targeted genes cannot be predicted. To solve this problem of the classical conditional and inducible KO approaches, researchers need to simultaneously knock out a gene in all cells locally-a process called the localized all-cell KO (LACKO) strategy. We describe the concept of this new strategy in detail in this article.

Entities:  

Mesh:

Year:  2012        PMID: 22695914     DOI: 10.1007/s11248-012-9622-2

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  12 in total

Review 1.  Reaching a genetic and molecular understanding of skeletal development.

Authors:  Gerard Karsenty; Erwin F Wagner
Journal:  Dev Cell       Date:  2002-04       Impact factor: 12.270

2.  Generation of Fgfr1 conditional knockout mice.

Authors:  Xiaoling Xu; Wenhui Qiao; Cuiling Li; Chu-Xia Deng
Journal:  Genesis       Date:  2002-02       Impact factor: 2.487

Review 3.  Genetically modified animals for use in research and biotechnology.

Authors:  L M Chaible; M A Corat; E Abdelhay; M L Z Dagli
Journal:  Genet Mol Res       Date:  2010-07-27

4.  Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene.

Authors:  H Shibata; K Toyama; H Shioya; M Ito; M Hirota; S Hasegawa; H Matsumoto; H Takano; T Akiyama; K Toyoshima; R Kanamaru; Y Kanegae; I Saito; Y Nakamura; K Shiba; T Noda
Journal:  Science       Date:  1997-10-03       Impact factor: 47.728

Review 5.  A novel transgenic mouse model to study the osteoblast lineage in vivo.

Authors:  Christa Maes; Tatsuya Kobayashi; Henry M Kronenberg
Journal:  Ann N Y Acad Sci       Date:  2007-11       Impact factor: 5.691

6.  Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation.

Authors:  Anne L Jacob; Craig Smith; Juha Partanen; David M Ornitz
Journal:  Dev Biol       Date:  2006-05-27       Impact factor: 3.582

Review 7.  The construction of transgenic and gene knockout/knockin mouse models of human disease.

Authors:  Alfred Doyle; Michael P McGarry; Nancy A Lee; James J Lee
Journal:  Transgenic Res       Date:  2011-07-29       Impact factor: 2.788

Review 8.  FGF signaling: its role in bone development and human skeleton diseases.

Authors:  Nan Su; XiaoLan Du; Lin Chen
Journal:  Front Biosci       Date:  2008-01-01

9.  Image-guided, noninvasive, spatiotemporal control of gene expression.

Authors:  Roel Deckers; Bruno Quesson; Josette Arsaut; Sandrine Eimer; Franck Couillaud; Chrit T W Moonen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

10.  Murine FGFR-1 is required for early postimplantation growth and axial organization.

Authors:  C X Deng; A Wynshaw-Boris; M M Shen; C Daugherty; D M Ornitz; P Leder
Journal:  Genes Dev       Date:  1994-12-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.